Clinical and translational gastroenterology · 2025
Dupilumab for Adult and Adolescent Patients With Primary Eosinophilic Colitis.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sia Twan, Bacchus Leeon, Kumar Aparna, Fikri Lina, Solecki Rachel, Herath Ramin, Bacchus Yeelin, Apollon Audrey, Werd Margaret, Ashraf Aseelah, Wu Elaine, Bahar Dan, Leung John
Аннотация
INTRODUCTION: Eosinophilic colitis (EoC) currently has limited options to induce histologic and clinical remission. Dupilumab is a human monoclonal antibody against the interleukin-4 receptor ɑ subunit effective in eosinophilic esophagitis (EoE) and other non-EoE eosinophilic gastrointestinal disorders.
METHODS: We conducted a retrospective chart review to assess the histoclinical response of patients with EoC treated with dupilumab.
RESULTS: Of 4 included patients, all 4 improved histologically, with 3 patients attaining histologic remission. All patients' symptom scores significantly improved, and 1 patient was asymptomatic on dupilumab.
DISCUSSION: This retrospective case series provides preliminary evidence that dupilumab may be an effective treatment option for EoC.
METHODS: We conducted a retrospective chart review to assess the histoclinical response of patients with EoC treated with dupilumab.
RESULTS: Of 4 included patients, all 4 improved histologically, with 3 patients attaining histologic remission. All patients' symptom scores significantly improved, and 1 patient was asymptomatic on dupilumab.
DISCUSSION: This retrospective case series provides preliminary evidence that dupilumab may be an effective treatment option for EoC.